Aspire Biopharma Hldgs Inc.
13F holders, Q2 2025 (June 30)16holders +1
10new positions
9sold out
$0.27avg. 13F price*
At the end of Q2 2025, 16 institutions reported holding Aspire Biopharma Hldgs Inc. in their 13F filings, up 1 from Q1 2025. 10 opened new positions and 9 sold out. The largest holders were Procyon Advisors, LLC ($174K), Crewe Advisors LLC ($169K) and Optivise Advisory Services LLC ($63K).
- Company
- Aspire Biopharma Hldgs Inc.
- CUSIP
- 738920107
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $72K |
| Exits | 9 | $506K |
All 13F filers, Q1 2025 → Q2 2025: 1,392,301 shares bought and 783,981 shares sold, net +608,320 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Procyon Advisors, LLC | 0.02% | Add +558.3% | 648,411 | $174K |
| Crewe Advisors LLC | 0.02% | Add +100.0% | 626,854 | $169K |
| Optivise Advisory Services LLC | 0.03% | Add +120.9% | 235,106 | $63K |
| Jane Street Group, LLC | 0.00% | Add +625.8% | 152,552 | $41K |
| VR Advisory Services Ltd | 0.01% | New | 97,391 | $26K |
| Three Seasons Wealth, LLC | 0.00% | New | 75,000 | $20K |
| Periscope Capital Inc. | 0.01% | No change | 75,000 | $15K |
| Valley Wealth Managers, Inc. | 0.00% | New | 40,000 | $11K |
| Platform Technology Partners | 0.00% | No change | 37,611 | $10K |
| Goldman Sachs Group Inc. | 0.00% | New | 18,701 | $5K |
| Scientech Research LLC | 0.00% | New | 16,514 | $4K |
| Allred Capital Management, LLC | 0.00% | New | 11,185 | $3K |
| CIBC Private Wealth Group LLC | 0.00% | New | 7,108 | $2K |
| Raymond James Financial Inc. | 0.00% | New | 2,500 | $673 |
| Bank of America Corp. | 0.00% | New | 271 | $73 |
| Osaic Holdings, Inc. | 0.00% | New | 100 | $26 |
"% of holder's portfolio" is ASPIRE BIOPHARMA HLDGS INC's weight in each manager's 13F, not the share of Aspire Biopharma Hldgs Inc. the manager owns.